-

European Union Artificial Intelligence (AI) Act and its Impact on Medical Device Manufacturers Training Course (November 8, 2022) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "EU (European Union) Artificial Intelligence (AI) Act and its Impact on Medical Device Manufacturers Training Course" conference has been added to ResearchAndMarkets.com's offering.

Many companies take part in the global 'race to AI' by continuously broadening the role of AI in their product portfolio. However, the rules of the game appear to be changing.

The increased visibility of the technology's risks has led to calls for regulators to look beyond the benefits, and also secure appropriate legislation to ensure AI that is 'trustworthy'- legal, ethical, and robust. During this session, we will discuss the main players, trends, and challenges in the 'race' to AI regulation and how companies can move forward with an advantage.

Benefits in Attending

  • Get up to speed with the proposed regulation
  • Understand the impact on machine learning medical devices
  • Gain an insight into this rapidly changing environment
  • Develop a competitive advantage

Who Should Attend:

  • Global Regulatory Senior Managers
  • Team Lead in Global Medical Device Management
  • Principal Regulatory Affairs Specialist
  • Regulatory Affairs Managers
  • Safety Scientists
  • Scientific Support Specialists
  • Software Engineers
  • Head of Product
  • Device Technical Lead
  • IT Quality Advisers

Key Topics Covered:

  • Welcome and introduction
  • Geopolitical considerations of AI legislation
  • Introduction to the proposed European AI Act
  • Impact of the proposed AI Act on medical device manufacturers
  • International overview of legislation affecting machine learning medical devices
  • Standardisation on AI and related data
  • Future perspectives
  • Q & A

For more information about this conference visit https://www.researchandmarkets.com/r/c3lhex

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Hexabromocyclododecane (CAS 25637-99-4) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Hexabromocyclododecane (CAS 25637-99-4) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. This report on Hexabromocyclododecane provides comprehensive insights, including general information, synonyms, chemical composition, safety, hazards, handling, storage, and toxicological and ecological details, along with transport information. This in-depth study serves as a v...

Commercial Gas Rice Cookers Market Report 2026: Revenues Set to Reach $2 Billion by 2032 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Commercial Gas Rice Cookers Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The Commercial Gas Rice Cookers Market is experiencing significant growth, evolving from USD 1.28 billion in 2025 to an anticipated USD 2.00 billion by 2032, driven by a CAGR of 6.52%. This market research report provides a comprehensive analysis of the commercial gas rice cooker sector, highlighting key drivers like foodservice efficiency, industria...

Artemisinin Combination Therapy Market to Grow by $194 Million During 2026-2032 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Artemisinin Combination Therapy Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The Artemisinin Combination Therapy (ACT) market exemplifies dynamic growth and promising potential in the treatment of malaria. Expected to increase from USD 386.40 million in 2025 to USD 608.26 million by 2032, supported by a steady CAGR of 6.69%, this market highlights the evolving landscape for modern antimalarial solutions. At the core of AC...
Back to Newsroom